Rimonci Capital

Rimonci Capital invests from Raanana, Israel, with checks of $1M to $5M at Series A and Series B. The firm bridges Israeli deep-tech innovation and global markets, with a concentrated focus on advanced medical devices, robotics, and digital health integrations. Founders pitching Rimonci are talking to investors who treat medtech and devices as their primary professional identity rather than as one slice of a generalist portfolio, which tends to make the conversation more substantive and the diligence more pointed.

The thesis covers medical devices and medtech and digital health, with strong attention to AI-enabled and robotics-driven products. Rimonci is most interested in companies whose technical work is genuinely differentiated and whose commercial path includes credible plans for both Western and Asian markets. The firm tends to back founders with deep technical or clinical backgrounds, often emerging from Israeli medical device companies, military R&D programs, or academic research, and the portfolio reflects that emphasis on engineering depth. Companies focused purely on consumer wellness or non-device healthcare software will find less alignment.

Check sizes of $1M to $5M place Rimonci as a participating or co-leading investor in Series A and Series B rounds. The geographic focus is Israel, with active engagement in helping portfolio companies expand into the United States, Europe, and Asia. The firm’s bridge to Asian markets, particularly China, has been a meaningful differentiator and shapes how it thinks about commercialization paths for portfolio companies. Founders should expect questions about regulatory strategy across multiple jurisdictions and about manufacturing and supply chain plans that work for medical devices at scale.

The team includes investors with backgrounds in medical device development, regulatory affairs, cross-border investing, and Israeli technology venture. That combination gives portfolio companies access to advisors who understand both the technical realities of medtech development and the practical mechanics of selling into different geographies, which is rarely available in a single firm.

Rimonci’s approach to working with founders is engaged and commercial. The firm typically takes board seats and engages on regulatory strategy, manufacturing, and international commercialization, particularly around expansion into Asian markets. Rimonci has co-invested with Israeli, US, and Asian healthcare-focused investors and has supported portfolio companies through follow-on rounds and strategic partnerships with global medtech players. Founders building advanced medical devices, robotics, or digital health products with a serious technical core, and who want an investor with both Israeli depth and Asian commercial reach, will find Rimonci a relevant choice. Founders pursuing software-only healthcare plays without a device or hardware element will find less natural alignment.